Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
36.52
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
7 No-Brainer Biotech Stocks to Add to Your Buy List
↗
June 09, 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.
Via
InvestorPlace
80 Biggest Movers From Yesterday
↗
May 04, 2022
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to...
Via
Benzinga
Harmony Biosciences: Q1 Earnings Insights
↗
May 03, 2022
Harmony Biosciences (NASDAQ:HRMY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
May 03, 2022
Via
Benzinga
Harmony Biosciences Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET
↗
April 21, 2022
Harmony Biosciences (NASDAQ:HRMY) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
↗
April 14, 2022
Upgrades
Via
Benzinga
24 Biggest Movers From Yesterday
↗
April 13, 2022
Gainers Vertical Aerospace Ltd. (NYSE: EVTL) Shares hiked 30.93% to close at $9.82 on Tuesday after Deutsche Bank initiated coverage of the stock. Peabody Energy Corporation (...
Via
Benzinga
Bristol Myers, Eli Lilly And 2 Others Prove You Can Still Make Money In Medical Stocks
↗
March 11, 2022
These four medical stocks are outperforming the lousy market for health care investors.
Via
Investor's Business Daily
Harmony Biosciences: Q4 Earnings Insights
↗
February 28, 2022
Harmony Biosciences (NASDAQ:HRMY) reported its Q4 earnings results on Monday, February 28, 2022 at 07:30 AM. Here's what investors need to know about the announcement....
Via
Benzinga
3 Desirable Drug Stocks With Very Promising Pipelines
↗
February 16, 2022
Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.
Via
InvestorPlace
Top Buzzing Stocks For 2022
↗
January 25, 2022
Before making investment decisions, investors like me seek valuable insight on which sectors and/or which stocks will be giving high returns. Let’s have a broad look at what happened in 2021 and what’s...
Via
Talk Markets
Datadog, Applied Materials Lead Five Stocks Near Buy Points For The New Year
↗
January 01, 2022
Your stocks to watch as 2022 starts include Datadog and chip Applied Materials.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
↗
December 01, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV
Via
Benzinga
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2021 Earnings Call Transcript
↗
November 09, 2021
HRMY earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2021
↗
November 04, 2021
Upgrades According to B. Riley Securities, the prior rating for Monroe Capital Corp (NASDAQ:
Via
Benzinga
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
↗
October 20, 2021
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Harmony Biosciences Shares Spike Higher
↗
October 19, 2021
Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35. The U.S. has...
Via
Benzinga
Topics
Stocks
52 Biggest Movers From Yesterday
↗
October 20, 2021
Gainers Xiaobai Maimai Inc. (NASDAQ: HX) shares climbed 42.6% to close at $9.51 on Tuesday. Xiaobai Maimai said Xiaobao An resigned as CEO. Kaival Brands Innovations Group...
Via
Benzinga
Why Harmony Biosciences Stock Is Up 15% Today
↗
October 19, 2021
The young biopharma outfit is set to become part of a major market index, which means a buying spree is on the radar.
Via
The Motley Fool
Topics
Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
October 19, 2021
Gainers Redhill Biopharma (NASDAQ:RDHL) stock increased by 18.27% to $5.76 during Tuesday's regular session. Redhill Biopharma's stock is trading at a volume of 2....
Via
Benzinga
Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge
↗
October 19, 2021
Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69. The U.S. has the...
Via
Benzinga
Topics
Stocks
Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Boosts FY21 Guidance
↗
October 19, 2021
Following the market opening Tuesday, the Dow traded up 0.29% to 35,361.89 while the NASDAQ rose 0.31% to 15,068.75. The S&P also rose, gaining 0.39% to 4,503.81. The U.S. has...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 06, 2021
Gainers TransCode Therapeutics (NASDAQ:RNAZ
Via
Benzinga
Harmony Biosciences's Return On Capital Employed Overview
↗
September 22, 2021
According to Benzinga Pro, during Q2, Harmony Biosciences (NASDAQ:HRMY) earned $23.31 million, a 60.41% increase from the preceding quarter. Harmony Biosciences also posted a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
↗
September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:
Via
Benzinga
Harmony Biosciences Holdings, Inc. (HRMY) Q2 2021 Earnings Call Transcript
↗
August 11, 2021
HRMY earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
85 Biggest Movers From Yesterday
↗
August 11, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...
Via
Benzinga
Harmony Biosciences Stock Is Trading Higher On $330M Financing Deal With Blackstone, Q2 Earning Beat Estimates
↗
August 10, 2021
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has entered into a $330 million financing collaboration with The Blackstone Group Inc (NYSE: BX). The...
Via
Benzinga
54 Stocks Moving In Tuesday's Mid-Day Session
↗
August 10, 2021
Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
↗
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.